WO1998037185A3 - Vectors for controlled gene expression - Google Patents

Vectors for controlled gene expression Download PDF

Info

Publication number
WO1998037185A3
WO1998037185A3 PCT/US1998/003092 US9803092W WO9837185A3 WO 1998037185 A3 WO1998037185 A3 WO 1998037185A3 US 9803092 W US9803092 W US 9803092W WO 9837185 A3 WO9837185 A3 WO 9837185A3
Authority
WO
WIPO (PCT)
Prior art keywords
vectors
gene expression
tetracycline
disclosed
regulated
Prior art date
Application number
PCT/US1998/003092
Other languages
French (fr)
Other versions
WO1998037185A2 (en
Inventor
Hong-Ji Xu
Christopher J Logothetis
Shi-Xue Hu
Yunli Zhou
Original Assignee
Univ Texas
Xu Hong Ji
Christopher J Logothetis
Hu Shi Xue
Yunli Zhou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Xu Hong Ji, Christopher J Logothetis, Hu Shi Xue, Yunli Zhou filed Critical Univ Texas
Publication of WO1998037185A2 publication Critical patent/WO1998037185A2/en
Publication of WO1998037185A3 publication Critical patent/WO1998037185A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Abstract

Disclosed are improved broad host range expression vectors wherein gene expression is tightly regulated by tetracycline. The disclosed tetracycline-responsive vectors provide for the creation of stable cell lines, and a method of controlled gene expression where the transient elimination of gene expression is indicated. Also disclosed are tetracycline regulated adenovirus vectors which may be efficiently propagated in 293 cells, along with other tetracycline regulated viral vectors. Also disclosed are methods of using the tetracycline regulated vectors in the treatment of diseases such as cancer.
PCT/US1998/003092 1997-02-20 1998-02-19 Vectors for controlled gene expression WO1998037185A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3875597P 1997-02-20 1997-02-20
US60/038,755 1997-02-20

Publications (2)

Publication Number Publication Date
WO1998037185A2 WO1998037185A2 (en) 1998-08-27
WO1998037185A3 true WO1998037185A3 (en) 1998-11-26

Family

ID=21901713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/003092 WO1998037185A2 (en) 1997-02-20 1998-02-19 Vectors for controlled gene expression

Country Status (1)

Country Link
WO (1) WO1998037185A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042581A1 (en) 1998-02-19 1999-08-26 Eastern Virginia Medical School RECOMBINANT ACTIVE HUMAN ZONA PELLUCIDA PROTEIN 3 (hZP3)
US7037663B2 (en) 1998-02-19 2006-05-02 Eastern Virginia Medical School Human zona pellucida protein 3 and uses thereof
FR2782732A1 (en) * 1998-08-28 2000-03-03 Transgene Sa INDUCTIBLE EXPRESSION SYSTEM
ES2259846T3 (en) * 1998-10-19 2006-10-16 Powderject Vaccines, Inc. MINIMUM PROMOTERS AND USE OF THE SAME.
AU1344200A (en) * 1998-11-06 2000-05-29 Musc Foundation For Research Development A method of treating tumors using fas-induced apoptosis
WO2000028062A1 (en) * 1998-11-09 2000-05-18 Aventis Pharma S.A. Novel system for regulating transgene expression
FR2786198B1 (en) * 1998-11-09 2003-02-14 Aventis Pharma Sa NEW SYSTEM FOR REGULATING EXPRESSION OF A TRANSGEN
CZ20013813A3 (en) * 1999-04-26 2002-02-13 Aventis Pharma S. A. Use of defective recombinant adenovirus vector containing nucleic acid encoding angiogenic factor for preparing a medicament intended for treating lung hypertension
FR2792531B1 (en) * 1999-04-26 2003-01-31 Aventis Pharma Sa USE OF DEFECTIVE RECOMBINANT ADENOVIRUS COMPRISING A NUCLEIC ACID ENCODING AN ANGIOGENIC FACTOR FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
EP1083230A1 (en) * 1999-09-10 2001-03-14 Academisch Medisch Centrum Amsterdam Viral replicons and viruses dependent on inducing agents
WO2002054851A2 (en) * 2001-01-12 2002-07-18 Sbarro Institute For Cancer Research And Molecular Medicine Inhibition of pathological angiogenesis in vivo
WO2002070719A2 (en) * 2001-01-19 2002-09-12 Trustees Of The University Of Pennsylvania Regulatable gene expression system
WO2002090533A2 (en) * 2001-05-07 2002-11-14 National Research Council Of Canada Enhanced production of recombinant proteins by transient transfection of suspension-growing mammalian cells
WO2003011118A2 (en) 2001-08-02 2003-02-13 Trinity Biomedical Technology Corporation Human zona pellucida proteins and methods of their use in diagnosing male infertility
WO2004026903A2 (en) * 2002-09-20 2004-04-01 Akzo Nobel N.V. Live antenuated parasite vaccine
WO2005037297A1 (en) * 2003-10-10 2005-04-28 Gary Aronson Compositions and methods for inhibiting cell senescence and hyperproliferative disorders
CN114410689B (en) * 2022-03-29 2022-06-17 北京循生生物医学研究有限公司 Preparation method for enhancing lethality of tumor infiltrating lymphocytes

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006910A1 (en) * 1992-09-18 1994-03-31 Canji, Inc. Gene therapy by retroviral vector with tumor suppressive gene
WO1994021115A1 (en) * 1993-03-25 1994-09-29 Baylor College Of Medicine Broad spectrum tumor suppressor genes, gene products and methods for tumor suppression gene therapy
WO1994028152A1 (en) * 1993-05-28 1994-12-08 Transgene S.A. Defective adenoviruses and corresponding complementation lines
WO1996001313A1 (en) * 1994-07-01 1996-01-18 Hermann Bujard Tetracycline-regulated transcriptional modulators
WO1996031242A1 (en) * 1995-04-07 1996-10-10 Albert Einstein College Of Medicine Of Yeshiva University RECOMBINANT β-CELL AND USES THEREOF
WO1996040946A1 (en) * 1995-06-07 1996-12-19 Yale University An autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006910A1 (en) * 1992-09-18 1994-03-31 Canji, Inc. Gene therapy by retroviral vector with tumor suppressive gene
WO1994021115A1 (en) * 1993-03-25 1994-09-29 Baylor College Of Medicine Broad spectrum tumor suppressor genes, gene products and methods for tumor suppression gene therapy
WO1994028152A1 (en) * 1993-05-28 1994-12-08 Transgene S.A. Defective adenoviruses and corresponding complementation lines
WO1996001313A1 (en) * 1994-07-01 1996-01-18 Hermann Bujard Tetracycline-regulated transcriptional modulators
WO1996031242A1 (en) * 1995-04-07 1996-10-10 Albert Einstein College Of Medicine Of Yeshiva University RECOMBINANT β-CELL AND USES THEREOF
WO1996040946A1 (en) * 1995-06-07 1996-12-19 Yale University An autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. HOFFMANN ET AL.,: "Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassete", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 93, 1996, WASINGTON, DC, US, pages 5185 - 5190, XP002015266 *
H-J. XU ET AL.,: "Enhanced tumor supressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein", CANCER RESEARCH, vol. 56, no. 10, 1996, OXFORD, GB, pages 2245 - 2249, XP002068733 *
H-J. XU ET AL.,: "Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition", ONCOGENE, vol. 15, no. 21, 1997, BASINGSTOCKE, GB, pages 2589 - 2596, XP002068735 *
M. GOSSEN AND H. BUJARD: "Tight control of gene expression in mammalian cells by tetracycline responsive promoters", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 89, no. 12, 1992, WASIHNGTON, DC, US, pages 5547 - 5551, XP000564458 *
S-X. HU ET AL.,: "Developement of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression", CANCER RESEARCH, vol. 57, no. 16, 15 August 1997 (1997-08-15), OXFORD, GB, pages 3339 - 3343, XP002068734 *

Also Published As

Publication number Publication date
WO1998037185A2 (en) 1998-08-27

Similar Documents

Publication Publication Date Title
WO1998037185A3 (en) Vectors for controlled gene expression
WO1998020145A3 (en) Improvements in or relating to starch content of plants
WO1995027071A3 (en) An adenovirus supervector system
GEP20012559B (en) Complementary Adenoviral Vector Systems and Cells Lines
AU9582398A (en) Methods and devices for the long-term culture of hematopoietic progenitor cells
NO964445L (en) DNA sequence, vector, host cell and method for transfecting hematopoietic cells with exogenous DNA
ATE295739T1 (en) ADENOVIRAL VECTORS INCLUDING A PROSTATE SPECIFIC ANTIGEN (PSA) ßRESPONSE ELEMENTß
EP0832203A4 (en) Use of neuro-derived fetal cell lines for transplantation therapy
AU716500B2 (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs
IE840258L (en) Expression of gene products.
CA2306449A1 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
WO1999023216A3 (en) Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
AU5318496A (en) Adenovirus vectors for gene therapy
WO2003089581A3 (en) A method to increase the rate of cell growth
BR9811014A (en) "concentrated gene regulatory region specifically for early seed"
CA2278808A1 (en) Methods for cultivating cells and propagating viruses
AU1705599A (en) Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood
AU3950799A (en) Genetically engineered yeast and mutants thereof for the efficient fermentation of lignocellulose hydrolysates
WO1996009399A3 (en) Chimeric adenovirus for gene delivery
CA2337088A1 (en) Methods and constructs for protein expression
AU3804997A (en) Vectors for inhibiting HIV and tumor growth
IL117470A0 (en) Sertoli cells as transplantation facilitator for cell transplantation
AU8119294A (en) Improved cell cultivation method and medium
ES2145051T3 (en) PROCEDURE FOR THE CULTIVATION OF A TYPE OF CELL IN THE LIVING CELL CULTIVATION PROCEDURE.
WO2001032898A3 (en) Recombinant sendai virus vector for introducing exogenous genes to airway epithelia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998536808

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase